LNTH - Lantheus climbs as outlook beats expectations

Healthcare supplier Lantheus Holdings (NASDAQ:LNTH) has added ~32% in the pre-market Thursday on above-average volume after the company set its outlook ahead of Wall Street forecasts on the back of a strong beat in its Q4 2021 financials. Worldwide revenue for the quarter and full-year jumped ~38% YoY and ~25% to reach $129.6M and $425.2M, respectively. However, quarterly net loss climbed to $40.2M from $3.4M in the prior-year period, and full-year net loss witnessed a five-fold rise to reach $71.3M. “This year is off to a similarly productive start as we received FDA approval for our on-site manufacturing facility for DEFINITY,” Chief Executive Officer Mary Anne Heino remarked. “In 2022, we will continue to advance our purpose to Find, Fight and Follow serious medical conditions to improve patient outcomes, and continue to drive revenue growth and shareholder value.” For the Q1 2022, Lantheus projects $160M - $170M and $0.45 - $0.50 adj. fully

For further details see:

Lantheus climbs as outlook beats expectations